KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001)

Kura Oncology

Status and phase: Enrolling; Phase 1

Conditions: Colorectal Cancer (CRC); Solid Tumors With HRAS Alterations; Clear Cell Renal Cell Carcinoma (ccRCC); Pancreatic Ductal Adenocarcinoma (PDAC); Non Small Cell Lung Cancer (NSCLC); Renal Cell Carcinoma (Kidney Cancer)

Treatments: Drug: Cabozantinib; Drug: Adagrasib; Drug: KO-2806

Study type: Interventional

Funder types: Industry

Identifiers

NCT06026410

KO-2806-001

Details and patient eligibility

About

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.

Enrollment: 270 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• At least 18 years of age.

• Histologically or cytologically confirmed advanced solid tumors

  • Arm #1 (Monotherapy): HRAS-mutant and/or amplified tumors (any solid tumor type); HRAS overexpression (only for HNSCC tumors); KRAS and/or NRAS, and/or HRAS-mutant and/or amplified NSCLC or CRC; KRAS-mutant and/or amplified PDAC
  • Arm #2 (Combination): Must have received at least 1 prior systemic therapy with IO-based treatment for locally advanced or metastatic RCC
  • Arm #3 (Combination): Must have KRAS G12C-mutant locally advanced or metastatic NSCLC, CRC, or PDAC and have received at least 1 prior systemic therapy for advanced or metastatic disease

• Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

• Karnofsky Performance Status of 70 or higher with no clinically significant deterioration over the previous 2 weeks.

• Acceptable liver, renal, endocrine, and hematologic function.

• Other protocol-defined inclusion criteria may apply.

Exclusion criteria

• Ongoing treatment with certain anticancer agents.
• Prior treatment with an FTI or HRAS inhibitor.
• Major surgery, other than local procedures, within 28 days prior to Cycle 1 Day 1, without complete recovery.
• Spinal cord compression, leptomeningeal disease, or clinically active CNS metastases.
• Toxicity (excluding alopecia) from prior therapy that has not been completely resolved to baseline at the time of consent.
• Active or prior documented autoimmune or inflammatory disorders within the past 5 years prior to Cycle 1 Day 1 (with exceptions).
• Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.
• Inability to swallow, impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the trial drugs.
• Inadequate cardiac and/or vascular function, including receipt of treatment for unstable angina, myocardial infarction, and/or cerebro-vascular attack within the prior 6 months, mean QTcF ≥470 ms, or Class II or greater congestive heart failure.
• Other invasive malignancy within 2 years.
• Other protocol-defined exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

270 participants in 3 patient groups

Arm #1: RAS-altered advanced solid tumors

Experimental group

Description:

Patients with advanced solid tumors and the following: * HRAS-mutant and/or amplified tumors (any solid tumor type) * HRAS overexpression (only for HNSCC tumors) * KRAS and/or NRAS and/or HRAS-mutant and/or amplified for NSCLC or CRC * KRAS-mutant and/or amplified PDAC

Treatment:

Drug: KO-2806

Arm #2: Advanced or metastatic RCC

Experimental group

Description:

Patients who have received at least 1 prior systemic therapy with IO-based treatment for locally advanced or metastatic RCC

Treatment:

Drug: KO-2806

Drug: Cabozantinib

Arm #3: Advanced or metastatic NSCLC, CRC, or PDAC

Experimental group

Description:

Patients with KRAS G12C-mutant locally advanced or metastatic NSCLC, CRC, or PDAC who have received at least 1 prior systemic therapy for advanced or metastatic disease

Treatment:

Drug: KO-2806

Drug: Adagrasib